MAPT and Alzheimer disease: However, as sarcopenia progresses, it is likely that poor muscle function, rather than reduced muscle mass, may drive the association between sarcopenia and late‐life cognitive impairment [28], which could explain the negative association between TMT and AD, as well as the later tau PET Braak stage (III‐VI) SUVR values observed in our study.